Latest Breaking News On - Fast track status - Page 16 : comparemela.com

ACADIA Pharmaceuticals : Net sales of $106 6 million, an 18% increase over 1Q20

- Reiterating FY21 net sales guidance of $510 to $550 million SAN DIEGO, CA, May 5, 2021 - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021. NUPLAZID delivered strong year-over-year performance in the first quarter of 2021. Looking ahead, we see positive signs in the Parkinson s disease psychosis market supporting revenue growth for the remainder of the year as we anticipate continued improvements in the conditions related to the pandemic, said Steve Davis, Chief Executive Officer. Furthermore, we look forward to a Type A meeting with the FDA to discuss an approval path for pimavanserin in dementia-related psychosis and we continue to advance our two Phase 3 programs for Rett syndrome and the negative symptoms of schizophrenia, as well as our Phase 2 pain program and earlier pipeline opportunities.

United statesSteve davisMark johnsonEric endicottCompany updatesDrug administrationExchange commissionAcadia pharmaceuticalsVanderbilt universityAcadia pharmaceuticals incChief executiveComplete response letterNew drug applicationWebcast informationFast track statusOrphan drug designation

(CANF) - Can-Fite BioPharma s Namodenoson Improves Liver Function, Long Term Data Shows

(CANF) - Can-Fite BioPharma s Namodenoson Improves Liver Function, Long Term Data Shows
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

European medicines agencyCan fite biopharmaEuropean medicinesOrphan drug designationFast track statusஐரோப்பிய மருந்துகள்ஆர்ஃபந் மருந்து பதவிவேகமாக டிராக் நிலை

Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Press release content from Business Wire. The AP news staff was not involved in its creation. Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal Cancers January 8, 2021 GMT PETACH TIKVA, Israel (BUSINESS WIRE) Jan 8, 2021 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced a scientific paper titled, “Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial” was published in the peer reviewed journal ADVERTISEMENT The paper highlights and analyzes results from Can-Fite’s Phase II study, a randomized placebo-controlled trial to investigate Namodenoson as a 2nd-line treatment for advanced hepatocellular carcinoma (HCC) and moderate hepatic dysfunction, as defined by Child–Pugh B (CPB) scores of 7–9. Even thoug

United statesFite biopharmaMotti farbsteinPnina fishmanExchange commissionFite biopharma ltdEuropean medicines agencyDrug administrationAdvanced hepatocellular carcinomaPughb cirrhosisRandomized placebo controlled clinicalOrphan drug statusFast track statusOrphan drug designationFast track designationCan fite biopharma